NCT05001516View on ClinicalTrials.gov

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-302

All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Trial Locations (7)

10016

Local Institution - 0018, New York

47905

Local Institution - 0012, Lafayette

73120

Local Institution - 0016, Oklahoma City

77030

Local Institution - 0015, Houston

91010

Local Institution - 0013, Duarte

92835

Local Institution - 0017, Fullerton

07652

Local Institution - 0020, Paramus

All Listed Sponsors
lead

Turning Point Therapeutics, Inc.

INDUSTRY

NCT05001516 - Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Biotech Hunter | Biotech Hunter